• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

Hermes US SMID Equity Fund Class F GBP Inc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider Hermes Investment Management Ltd
Fund Summary The investment objective of the fund is to provide long-term capital appreciation by investing primarily in equity or equity related securities of small and mid-capitalisation companies domiciled in the US, or which derive a large proportion of their income from US activities. These are primarily listed or traded in the US or Canada.
SEDOL code B8493D2
ISIN IE00B8493D29
Fund code HUSMI
Managers Michael Russell, Mark Sherlock
Manager Tenure 5 years
Morningstar Category US Mid-Cap Equity
IMA Sector North American Smaller Companies
Fund Size £746 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.85%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £2.246
Buy Price £2.246
Price Change +1.3035%
Price Date 20th August 2019
Yield 0.02%
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 13th May 2013
Fund Status OPEN
Michael joined Hermes in March 2014 as the co-manager of the US SMID Cap strategy and became the lead manager of the US All Cap strategy in May 2015. Michael was most recently senior portfolio manager of the Global Developed Markets Equity funds at Normura Asset Management, where he worked for eight years. During this time he also acted as portfolio manager of the firms US equity funds for five years from 2005. Earlier in his career Michael held senior roles managing US equity funds at Merrill Lynch Investment Managers and Mercury Asset Management. He is a CFA charterholder and has an MA in Economics from Cambridge University.

3-year Mean Monthly Return: 1.033%

Annual Returns 2018 2017 2016 2015 2014 2013
Fund Performance +6.88% +9.36% +20.85% +18.51% +16.85% +8.95%
Benchmark Performance
(US Mid-Cap Equity)
+7.65% +14.87% +12.44% +14.90% +19.61%
Time Period Cumulative Benchmark Performance
(US Mid-Cap Equity)
Fund Compared to Benchmark
1 day 1.30% -0.40% +1.71%
1 week 1.04% +1.31% -0.27%
1 month 2.44% +1.98% +0.46%
3 months 7.65% +4.92% +2.73%
6 months 12.72% +8.35% +4.37%
1 year 3.32% +3.22% +0.10%
3 years 35.48% +44.33% -8.85%
5 years 99.64% +81.24% +18.40%
10 years Currently unavailable +273.83% Currently unavailable
YTD 25.39% +16.83% +8.56%
Since inception 123.84% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
West Pharmaceutical Services Inc USA 2.75%
Teradyne Inc USA 2.66%
Community Bank System Inc USA 2.60%
Alleghany Corp USA 2.60%
Reinsurance Group of America Inc USA 2.54%
AptarGroup Inc USA 2.48%
Wintrust Financial Corp USA 2.46%
Alimentation Couche-Tard Inc Class B CAN 2.45%
A.O. Smith Corp USA 2.10%
STERIS Ltd USA 2.09%
Dividend Date Per share amount Reinvestment Price
1st July 2019 0.0006 £2.2000
2nd January 2018 0.0003 £1.8943
3rd January 2017 0.0003 £1.8770
1st July 2016 0.0005 £1.5787
31st December 2015 0.0001 £1.3126
31st December 2014 0.0001 £1.2308